Instil Bio cuts US headcount to ~15, consolidates operations to UK, expects cash runway beyond 2026

Instil Bio, Inc.

Will extend reduction-in-force to ~15 US employees; transition ITIL-306 manufacturing and trial to Manchester, UK.
Estimates total restructuring costs up to $3.0M, excluding potential facility sale charges.
Evaluating potential sale/sublease of Tarzana, CA manufacturing site to further extend cash runway.
Expects cash runway beyond 2026; initial ITIL-306 clinical data still expected in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.